Aesica, the global contract development and manufacturing organisation (CDMO), announced the appointment of Adam Burgess to the position of Product Release Manager. His role includes managing the Qualified Persons team; directing and controlling QP activities in line with operational requirements, the role also involves the development of quality systems, product release, facilitating process improvements and acting as a Qualified Person.

Based at Queenborough, UK Burgess has responsibility for pharmaceutical quality assurance across the Kent based site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organisational structures.

Previously, he held the position of Manager, Defective Medicines Report Centre and Import Notification at the MHRA and was an active Qualified Person at Martindale Pharma. Prior to that, he worked as a QA Manager in Preclinical Quality Assurance at GlaxoSmithKline. His expertise reaches across both commercial and clinical trial products including steriles, non-sterile tablets, capsules and liquids.

Remarking on his new position, Adam Burgess said: "I am delighted to be appointed to this role at Aesica. It affords me the opportunity to return to pharmaceutical manufacturing and packaging, bringing the experience that I have gained at the UK regulator. This experience will help me to further enhance and drive quality culture initiatives across the company - in particular at Queenborough. I am looking forward to leading the Product Release team to ensure that all staff fully understand customer needs, consistently deliver results, whilst maintaining the high quality levels demanded and expected." 

Commenting on Adam Burgess's appointment, Indira Walker, Corporate Quality Director at Aesica remarked: "We are delighted that Adam has joined our Quality Assurance team. He brings strong Quality Assurance expertise and we are especially impressed by his combined experience of working both for prominent pharmaceutical companies and the MHRA regulatory authority."